2-bromophenylacetaldehyde diethylacetal | 1443347-25-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromophenylacetaldehyde diethylacetal
• 英文别名: 1-Bromo-2-(2,2-diethoxyethyl)benzene
• CAS: 1443347-25-8
• 化学式: C₁₂H₁₇BrO₂
• 分子量: 273.17
• InChiKey: PWLJWZOGKQEYFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromophenylacetaldehyde diethylacetal 在 甲胺 作用下， 以 甲醇 、 二氧化碳 、 氮 为溶剂， 生成 2-methylaminophenylacetaldehyde diethylacetal
  参考文献：
  名称：

  Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases

  摘要：

  本发明提供了一种治疗哺乳动物自身免疫疾病以及预防或治疗移植受体的移植排斥的方法。这些方法利用特定定义的甲巯咪唑衍生物和互变环硫醇化合物，以及含有这些化合物的药物组合物。已发现这些化合物和组合物在药物活性方面至少与甲巯咪唑同样有效，同时对甲状腺功能的不良影响更小。它们在常规药物载体中的溶解度也比甲巯咪唑更高。还教授了一种用于筛选对自身免疫疾病有用的化合物活性（抑制MHC I和II分子表达能力）的检测方法。

  公开号：

  US06365616B1

文献信息

• OLIGOMERISATION OF ETHYLENE TO MIXTURES OF 1-HEXENE AND 1-OCTENE
  申请人：SASOL TECHNOLOGY (PROPRIETARY LIMITED)

  公开号：US20160083311A1

  公开（公告）日：2016-03-24

  A process for the oligomerisation of ethylene to predominantly 1-hexene or 1-octene or mixtures of 1-hexene and 1-octene includes contacting ethylene with a catalyst under ethylene oligomerisation conditions. The catalyst comprises a source of chromium, a diphosphine ligating compound, and optionally an activator. The diphosphine ligating compound includes at least one optionally substituted fused cyclic structure including at least two rings, the optionally substituted fused cyclic structure including a 5- to 7-membered aromatic first ring bonded to a phosphorus atom, the aromatic first ring being fused to a 4- to 8-membered heterocyclic second ring, the heterocyclic second ring including a heteroatom which is separated by two ring atoms along the shortest connecting path from the phosphorous atom that is bonded to the first aromatic ring.

  一种用于以乙烯为原料进行低聚乙烯反应制备1-己烯或1-辛烯或1-己烯和1-辛烯混合物的方法，包括在乙烯低聚反应条件下将乙烯与催化剂接触。所述催化剂包括铬源、二膦配合物和可选的活化剂。所述二膦配合物包括至少一个可选取代的融合环结构，包括至少两个环，所述可选取代的融合环结构包括与磷原子键合的5-至7-成员芳香第一环，所述芳香第一环与4-至8-成员杂环第二环融合，所述杂环第二环包括一个杂原子，该杂原子沿着与第一芳香环键合的磷原子之间的最短连接路径与之分离。
• METHIMAZOLE DERIVATIVES AND TAUTOMERIC CYCLIC THIONES TO TREAT AUTOIMMUNE DISEASES
  申请人：Sentron Medical, Inc.

  公开号：EP1112072A2

  公开（公告）日：2001-07-04
• US6365616B1
  申请人：——

  公开号：US6365616B1

  公开（公告）日：2002-04-02
• US9533922B2
  申请人：——

  公开号：US9533922B2

  公开（公告）日：2017-01-03
• [EN] METHIMAZOLE DERIVATIVES AND TAUTOMERIC CYCLIC THIONES TO TREAT AUTOIMMUNE DISEASES<br/>[FR] DERIVES DE METHIMAZOLE ET THIONES CYCLIQUES TAUTOMERES PERMETTANT DE TRAITER LES MALADIES AUTO-IMMUNES
  申请人：SENTRON MEDICAL INC

  公开号：WO2000012175A2

  公开（公告）日：2000-03-09

  The present invention provides methods for treating autoimmune diseases in mammals and for preventing or treating transplantation rejection in a transplant recipient. These methods utilize specifically-defined methimazole derivatives and tautomeric cyclic thione compounds, as well as pharmaceutical compositions containing those compounds. These compounds and compositions have been found to be at least as effective as methimazole in terms of pharmaceutical activity, while having less of an adverse effect on thyroid function. They are also more soluble in conventional pharmaceutical vehicles than methimazole. An assay for screening the activity of compounds useful against autoimmune diseases (ability to suppress expression of MHC Class I and II molecules) is also taught.